A long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice

• Päätekijät: Kripa Shankar (Tekijä), Nathan P. Metzger (Tekijä), Connor Lawrence (Tekijä), Deepali Gupta (Tekijä), Sherri Osborne-Lawrence (Tekijä), Salil Varshney (Tekijä), Omprakash Singh (Tekijä), Corine P. Richard (Tekijä), Alexander N. Zaykov (Tekijä), Rebecca Rolfts (Tekijä), Barent N. DuBois (Tekijä), Diego Perez-Tilve (Tekijä), Bharath K. Mani (Tekijä), Suntrea T.G. Hammer (Tekijä), Jeffrey M. Zigman (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2024-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Objective: The number of individuals affected by metabolic dysfunction associated fatty liver disease [1] is on the rise, yet hormonal contributors to the condition remain incompletely described and only a single FDA-approved treatment is available. Some studies suggest that the hormones ghrelin and...